Deliver Your News to the World

SmallCapNewsRelease:(OTCBB: CNDO) Moves Up to NASDAQ Listing


WEBWIRE

JERICHO, NY—(SmallCapNewsRelease)—December 16, 2011, Coronado Biosciences, Inc. (OTCBB: CNDO) has announced they have been approved for listing on the NASDAQ Capital Market and they expect to begin trading on Monday, December 19, 2011 under the symbol (NASDAQ: CNDO).
 
Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The Company’s two principal pharmaceutical product candidates in clinical development are: CNDO-201, a biologic for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors.
 
To view the entire press release, please visit, http://finance.yahoo.com/news/Coronado-Biosciences-Approved-pz-2705905445.html?x=0
 
SmallCapNewsRelease gainers are ISTA Pharma (NASDAQ: ISTA) RSC Holdings Inc (NYSE: RRR) CryptoLogic (NASDAQ: CRYP) Morton’s Restaurant Group (NYSE: MRT) Agria Corp (NYSE: GRO) Imperial Holdings (NYSE: IFT) Deer Consumer (NASDAQ: DEER) Mackinac Financial (NASDAQ: MFNC)
 
SmallCapNewsRelease decliners are StemCells, Inc (NASDAQ: STEM) Quantum Fuel Systems (NASDAQ: QTWW) Empire Resorts (NASDAQ: NYNYD) Kensey Nash Corp (NASDAQ: KNSY) Inhibitex, Inc (NASDAQ: INHX) Seanergy Maritime (NASDAQ: SHIP) Cablevision Systems (NYSE: CVC) Palmetto Bancshares (NASDAQ: PLMT)
 
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid SmallCapNewsRelease one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation do no trading of any kind and send no Faxes or emails.



WebWireID150599




 
 NASDAQ
 CNDO
 Leukemia
 SmallCapNewsRelease
 OTCBB


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.